US Stock Insider Trading | SI-BONE Discloses 23 Insider Transactions on February 18

2026-02-20 09:13:20

On February 18, 2026, SI-BONE (SIBN) disclosed 23 insider trading transactions. Director FRANCIS LAURA sold 39,800 shares on February 17, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 18, 2026	Director	FRANCIS LAURA	February 17, 2026	Sell	7,888	15.44	121,800
February 18, 2026	Director	FRANCIS LAURA	February 17, 2026	Sell	18,900	15.32	289,400
February 18, 2026	Director	FRANCIS LAURA	February 17, 2026	Sell	15,600	15.35	239,000
February 18, 2026	Director	FRANCIS LAURA	February 17, 2026	Sell	39,800	15.29	608,100
February 18, 2026	Director	FRANCIS LAURA	February 17, 2026	Sell	2,033	15.30	31,100
February 18, 2026	Director	FRANCIS LAURA	February 17, 2026	Sell	3,203	15.31	49,000
February 18, 2026	Director	FRANCIS LAURA	February 17, 2026	Sell	3,893	15.29	59,500
February 18, 2026	Director	FRANCIS LAURA	February 17, 2026	Sell	2,236	15.29	34,200
February 18, 2026	Executive	Maheshwari Anshul	February 17, 2026	Sell	1,279	15.35	19,600
February 18, 2026	Executive	Maheshwari Anshul	February 17, 2026	Sell	2,189	15.29	33,500

[Company Profile]

SI-BONE, Inc. was incorporated on March 18, 2008, in Delaware and is headquartered in Santa Clara, California. The company is a medical device firm dedicated to addressing musculoskeletal disorders of the sacropelvic anatomy. Using knowledge of pelvic anatomy and biomechanics, the company pioneered proprietary minimally invasive surgical implant systems to treat sacroiliac joint dysfunction and unmet clinical needs in pelvic fusion, fixation, and pelvic fracture management. Its products include a range of patented titanium implants and the instruments used to implant them. Since launching the first-generation iFuse in 2009, the company has introduced three new implant lines: iFuse-3D in 2017, iFuse-TORQ in 2021, and iFuse Granite in 2022. In the United States, the company’s iFuse, iFuse-3D, and iFuse-TORQ implant systems are approved for use in sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes